Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-01-27
Last Posted Date
2011-10-27
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
26
Registration Number
NCT00039468
Locations
🇺🇸

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States

🇺🇸

Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 1
Completed
Conditions
Lung Cancer
First Posted Date
2003-01-27
Last Posted Date
2008-07-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00045604
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer

First Posted Date
2003-01-27
Last Posted Date
2023-07-06
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
94
Registration Number
NCT00042939

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
Drug: Capecitabine
Drug: Irinotecan
First Posted Date
2003-01-27
Last Posted Date
2016-04-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
67
Registration Number
NCT00022698
Locations
🇺🇸

Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States

🇺🇸

Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States

🇺🇸

George Washington University Medical Center, Washington, District of Columbia, United States

and more 14 locations

Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-01-27
Last Posted Date
2014-08-22
Lead Sponsor
Duke University
Registration Number
NCT00005951
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer

Phase 3
Completed
Conditions
Colorectal Cancer
First Posted Date
2003-01-27
Last Posted Date
2021-02-17
Lead Sponsor
UNICANCER
Registration Number
NCT00005979
Locations
🇫🇷

Centre Hospitalier de Fleyriat, Bourg-En-Bresse, France

🇫🇷

Centre Leon Berard, Lyon, France

🇫🇷

Institut Bergonie, Bordeaux, France

and more 27 locations

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach

First Posted Date
2003-01-27
Last Posted Date
2020-08-03
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
51
Registration Number
NCT00020761
Locations
🇺🇸

OHSU Cancer Institute, Portland, Oregon, United States

🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 1 locations

Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

First Posted Date
2003-01-27
Last Posted Date
2023-06-28
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
97
Registration Number
NCT00033657
Locations
🇺🇸

CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States

🇺🇸

Ireland Cancer Center, Cleveland, Ohio, United States

🇺🇸

CCOP - Christiana Care Health Services, Newark, Delaware, United States

and more 20 locations

A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer

First Posted Date
2002-10-25
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
57
Registration Number
NCT00048126

A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer

First Posted Date
2002-10-25
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
52
Registration Number
NCT00048139
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy